Liver-specific reduction of Mfn2 protein by RNAi results in impaired glycometabolism and lipid homeostasis in BALB/c mice

Abstract

Mitofusin-2 (Mfn2) gene expression is positively correlated with insulin sensitivity in patients with type 2 diabetes. However, it is unclear if Mfn2 is involved in carbohydrate metabolism and lipid homeostasis. In order to investigate the specific functions of Mfn2 in glycometabolism and lipid homeostasis in BALB/c mice, a RNA interference technique-mediated hydrodynamic injection was developed, in which short hairpin RNAs (shRNAs) were used to inhibit the Mfn2 expression in vivo. Seventy-two mice were randomly divided into two groups: the Mfn2 reduction group (Mfn2/shRNA) and the negative control group (NC). Intraperitoneal glucose tolerance tests and intraperitoneal insulin tolerance tests were used to evaluate glycometabolism and insulin sensitivity. D-(3-³H) glucose or ³H₂O was injected into the tail vein or intraperitoneally to facilitate the calculation of the rate of hepatic glucose production and fatty acid synthesis in vivo. The results showed that, in Mfn2/shRNA mice, the liver Mfn2 protein was significantly decreased, and fasting blood glucose concentrations were increased by approximately 48%, when compared with the NC mice. In parallel with the changes in fasting glucose levels, hepatic glucose production was significantly elevated in Mfn2/shRNA mice. When insulin was administrated, these mice exhibited impaired insulin tolerance. It was also found that the reduction of Mfn2 markedly decreased the rate of fatty acid synthesis in the liver, and the Mfn2/shRNA mice exhibited hypertriglyceridema. Taken together, our results indicate that Mfn2 plays an important role in maintaining glucose and lipid homeostasis, and in the development of insulin resistance in vivo.

Keywords

Mitofusin-2 / RNA interference / glycometabolism / lipid homeostasis

References

[1] MLeeH.K., ParkK.S., ChoY.M., et al.. Mitochondria-based model for fetal origin of adult disease and insulin resistance. Ann NY Acad Sci, 2005, 1042(5): 1-18

[2] MorinoK., PetersenK.F., DufourS., et al.. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest, 2005, 115(12): 3587-3593

[3] MorinoK., PetersenK.F., ShulmanG.I.. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes, 2006, 55(Suppl2): S9-S15

[4] BegricheK., IgoudjilA., PessayreD., et al.. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion, 2006, 6(1): 1-28

[5] NishikawaT., KukidomeD., SonodaK., et al.. Impact of mitochondrial ROS production in the pathogenesis of insulin resistance. Diabetes Res Clin Pract Suppl, 2007, 77(Suppl1): S161-S164

[6] KarbowskiM., YouleR.J.. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Diff, 2003, 10(8): 870-880

[7] ChenH., DetmerS.A., EwaldA.J., et al.. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol, 2003, 160(2): 189-200

[8] ShinjiH., TakeshiA., MasayasuH., et al.. Mutational analysis of action of mitochondrial fusion factor mitofusin-2. J Cell Sci, 2005, 118(14): 3 153-3 161

[9] ChenH., ChomynA., ChanD.C.. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem, 2005, 280(28): 26 185-26 192

[10] DanielB., DeborahN., SaraP., et al.. Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle. Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6. Diabetes, 2005, 54(9): 2685-2693

[11] DanielB., SaraP., FrancescX.S., et al.. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem, 2, 2003, 278(19): 17 190-17 197

[12] MingroneG., MancoM., CalvaniM., et al.. Could the low level of expression of the gene encoding skeletal muscle mitofusin-2 account for the metabolic inflexibility of obesity?. Diabetologia, 2005, 48(10): 2108-2114

[13] PlomgaardP., NielsenA.R., FischerC.P., et al.. Associations between insulin resistance and TNF-α in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia, 2007, 50(12): 2562-2571

[14] JiaoK., LiuH., ChenJ., et al.. Roles of plasma interleukin-6 and tumor necrosis factor-a and FFA and TG in the development of insulin resistance induced by high-fat diet. Cytokine, 2008, 42(2): 161-169

[15] HuiG., GalinaB., ErikH., et al.. Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: A possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol Endocrinol, 2006, 20(6): 1287-1299

[16] CullenM.T., KohjiroU., KahnC.R.. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest, 2005, 115(3): 718-727

[17] LipingQ., PaulS.M., HanningY., et al.. Knocking down liver CCAAT/enhancer-binding protein by adenovirus-transduced silent interfering ribonucleic acid improves hepatic gluconeogenesis and lipid homeostasis in db/db mice. Endocrinology, 2006, 147(6): 3060-3069

[18] HetenyiG.Jr, NorwichK.H.. Validity of the rates of production and utilization of metabolites as determined by tracer methods in intact animals. Fed Proc, 1974, 33(7): 1841-1846

[19] DavidS., RogerW.B., MarcoC., et al.. Acute effects in vivo of anti-insulin serum on rates of fatty acid synthesis and activities of acetyl-coenzyme A carboxylase and pyruvate dehydrogenase in liver and epididymal adipose tissue of fed rats. Biochem J, 1976, 160: 413-416

[20] GastaldiG., RussellA., GolayA., et al.. Upregulation of peroxisome proliferator-activated receptor gamma coactivator gene (PGC1A) during weight loss is related to insulin sensitivity but not to energy expenditure. Diabetologia, 2007, 50(11): 2348-2355

[21] ErweiS., Sang-kyungL., JieW., et al.. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med, 2003, 9(3): 347-351

[22] XuJ.F., LiL., QianZ.K., et al.. Reduction of PTP1B by RNAi upregulates the activity of insulin controlled fatty acid synthase promoter. Biochem Biophys Res Commun, 2005, 329(2): 538-543

[23] WangN., SunY.H., LiuJ., et al.. Knock down of gfp and no tail expression in zebrafish embryo by in vivo-transcribed short hairpin RNA with T7 plasmid system. J Biomed Sci, 2007, 14(6): 767-776

[24] GiovannaA., MaristellaR., DiegoG., et al.. Gene silencing of human RAMP2 mediated by short-interfering RNA. Int J Mol Med, 2006, 18(4): 531-535

[25] ShawnD.L., LindseyN.J., AndyC., et al.. Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery, 2007, 142(2): 262-269

[26] DagR.S., MarianneL., MouldyS.. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol, 2003, 327(4): 761-766

[27] XavierC., Chu-XiaD.. RNAi in mice: a promising approach to decipher gene functions in vivo. Biochimie, 2006, 88(6): 637-643